Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai Transfers Tazemetostat Royalty Rights Outside Japan to US Firm
Eisai said on November 5 that it has entered into an agreement to transfer the rights to receive royalties on sales outside Japan for the investigational anticancer agent tazemetostat (development code: E7438) to US-based Royalty Pharma. Discovered by US biotech…
To read the full story
Related Article
- Eisai Revises Deal with Epizyme on Cancer Therapies
March 13, 2015
- Eisai Ties Up with Epizyme for Cancer Treatments
March 21, 2011
BUSINESS
- Japan’s Big 4 Drug Wholesalers See Profit Pressure Intensify in FY2025
May 19, 2026
- Asahi Kasei Starts Japan PIII of Extended Teribone Dosing
May 19, 2026
- Allergan Files Botox Vista for Forehead Wrinkles
May 19, 2026
- Stella Begins Japan PIII of BNCT for Recurrent Glioblastoma
May 19, 2026
- Enhertu Earns 2 US Approvals in HER2-Positive Early Breast Cancer
May 19, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…